PeptideStack
5.2kquestions
20kanswers
220users

Does splitting a 2 mg weekly dose of dulaglutide across two administrations change anything?

Asked 15 Jun 2024Modified 2.1 years agoViewed 10k times
9

What I have: 2 mg · dulaglutide.

I suspect the usual explanation for this is wrong, or at least incomplete.

I am aware this may have a boring answer. I would still like the boring answer stated clearly.

So what is the mechanism, and how well established is it?

split-dosing
split-dosing

Dividing a weekly dose across more than one administration. Questions here concern the pharmacokinetic rationale, whether the peak-to-trough ratio…

39 questionsdosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

811 questionsglp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

175 questionsdulaglutide
dulaglutide

A once-weekly GLP-1 receptor agonist built on an Fc fusion rather than fatty-acid acylation. Use this tag for questions about the fusion-protein…

14 questions
shareeditfollowflag
EL
askedesben_lykke15k2815 Jun 2024
5Worth adding that the method section is where the answer usually is. – h_pergande 9 months ago
add a comment

No answers yet

This question has not been answered. It has been viewed 10k times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.